Mission At FUJIFILM Diosynth Biotechnologies our mission is to become the leading and most trusted global CDMO in the industry, and our purpose is to become Partners for Life, Advancing Tomorrow’s Medicine
Description FUJIFILM Diosynth Biotechnologies is a Contract Development and Manufacturing Organization (CDMO) with a team of more than 4,200 amazing employees focused on achieving our global vision – to be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry.
As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, develop their processes, and strengthen their innovation. When our customers achieve milestones with their potential cures, vaccines, and biologics, we know our partnership and expertise helped make it happen.
Our focus is to combine technical leadership in cell culture, microbial fermentation, and cell and gene therapies with world class cGMP manufacturing facilities to advance tomorrow’s medicines.
Since 2019 we have invested more than $7 Billion USD in expansion projects at our facilities across the globe. Our growing locations increase our capabilities and expand our need for passionate, mission-driven individuals who want to make a real difference in people’s lives.
At Grifols, what we do is important.
Are you passionate about making a difference in the world? At Grifols, we are pioneers in the development of therapies derived from blood and plasma. We are helping to build the future of the healthcare sector to improve people's well-being. Since 1909, we have been defined by passion, innovation, teamwork and a sense of responsibility. Our people change lives while growing and developing in a forward-looking international company.
United Therapeutics Corporation (UT) was founded by parents trying to save the life of their child who had been diagnosed with a rare and terminal disease we now call pulmonary arterial hypertension (PAH). At the time, there were limited therapies, and the only known cure was then—and still is today—a lung transplant. Saving lives has always been our priority. That is why, following the overwhelming approval by our shareholders in 2021, UT became the first-ever publicly traded biotechnology company organized as a public benefit corporation (PBC). This aligns our legal form with our longstanding commitment to serve our patients. We believe it also enhances our ability to create superior and sustainable value for all our stakeholders, including our shareholders.
Fujifilm Diosynth Biotechnologies has an employee rating of 2.7 out of 5 stars, based on 598 company reviews on Glassdoor which indicates that most employees have an average working experience there. The Fujifilm Diosynth Biotechnologies employee rating is 23% below average for employers within the Pharmaceutical & Biotechnology industry (3.5 stars).
72% of job seekers rate their interview experience at Fujifilm Diosynth Biotechnologies as positive. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Fujifilm Diosynth Biotechnologies.